Tim R. Eijgenraam

Groningen, GR 9713GZ, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment.

In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment.

Journal: Cardiovascular research
Published: December 23, 2024

The impact of a humanized bile acid composition on atherosclerosis development in hypercholesterolaemic Cyp2c70 knockout mice.

The impact of a humanized bile acid composition on atherosclerosis development in hypercholesterolaemic Cyp2c70 knockout mice.

Journal: Scientific reports
Published: April 09, 2024

Elevated plasma bile acids coincide with cardiac stress and inflammation in young Cyp2c70-/- mice.

Elevated plasma bile acids coincide with cardiac stress and inflammation in young Cyp2c70-/- mice.

Journal: Pediatric research
Published: January 18, 2024

DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters.

DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters.

Journal: Circulation research
Published: November 13, 2023

Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population.

Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population.

Journal: European journal of internal medicine
Published: October 29, 2022

Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies.

Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies.

Journal: Journal of molecular and cellular cardiology
Published: July 13, 2022

Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation.

Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation.

Journal: International journal of molecular sciences
Published: January 13, 2022

Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy.

Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy.

Journal: Circulation. Heart failure
Published: September 30, 2021

Author Correction: The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy.

Author Correction: The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy.

Journal: Scientific reports
Published: October 03, 2020

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy.

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy.

Journal: Nature communications
Published: October 03, 2020

Strength of patient cohorts and biobanks for cardiomyopathy research.

Strength of patient cohorts and biobanks for cardiomyopathy research.

Journal: Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
Published: August 12, 2020

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy.

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy.

Journal: Scientific reports
Published: January 28, 2020
Showing 1-12 of 15

Last Updated: 09/26/2026